The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings-Reference-Cited by-同舟云学术

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings

Published:2017-03-17 Issue:9 Volume:37 Page:1325-1333
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Sezaki Hitomi¹^ORCID,Suzuki Fumitaka¹²,Hosaka Tetsuya¹,Akuta Norio¹,Fujiyama Shunichiro¹,Kawamura Yusuke¹,Kobayashi Masahiro¹,Suzuki Yoshiyuki¹,Saitoh Satoshi¹,Arase Yasuji¹,Ikeda Kenji¹,Kobayashi Mariko³,Kumada Hiromitsu¹

Affiliation:

1. Department of Hepatology; Toranomon Hospital; Tokyo Japan

2. Okinaka Memorial Institute for Medical Research; Tokyo Japan

3. Research Institute for Hepatology; Toranomon Hospital; Tokyo Japan

Funder

Ministry of Health, Labour and Welfare

Japan Agency for Medical Research and Development

Mitsui Life Social Welfare Foundation

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13384/fullpdf

Reference25 articles.

1. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study;Fried;Hepatology,2013

2. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan;Kumada;J Hepatol,2012

3. Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study;Hayashi;J Gastroenterol,2015

4. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection;Kumada;Hepatology,2014

5. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection;Afdhal;New Engl J Med,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of direct acting antiviral therapy on liver stiffness measured by using fibro scan in Egyptian patients with chronic hepatitis C;Medicinski Glasnik;2022-12-01

2. Precipitating factors causing hyperbilirubinemia during chronic hepatitis C treatment with paritaprevir/ritonavir/ombitasvir and dasabuvir;Journal of the Chinese Medical Association;2020-12

3. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis;Alimentary Pharmacology & Therapeutics;2019-12-10

4. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma;Alimentary Pharmacology & Therapeutics;2019-12-06

5. Real‐life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance‐associated substitution test;Journal of Medical Virology;2019-09-09